The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913.
OBJECTIVE
We attempt to elucidate the performance of serum prostate specific antigen (PSA) as a screening test for prostate cancer.


METHODS
We analyzed sera stored since 1980 in a nested case-control study.


RESULTS
The 36 patients with prostate cancer had a markedly greater mean serum PSA level than did 68 subjects without cancer (22.71 versus 2.67, respectively, p < 0.0001). Among the controls 24% had a serum PSA of greater than 4.0 micrograms/l. A serum PSA value exceeding 4.0 micrograms/l. in 1980 was associated with a 20-fold excess risk of cancer between 1981 and 1986, and an 8-fold risk between 1987 and 1991.


CONCLUSIONS
Diagnosis of clinically significant prostate cancer can be advanced substantially by serum PSA testing. However, the large number of high serum PSA values in men who remained free of clinical disease emphasizes the need for a more specific screening test.
Tibblin
G
G
Department of Family Medicine, University Hospital, Uppsala, Sweden.
Welin
L
L
Bergström
R
R
Ronquist
G
G
Norlén
B J
BJ
Adami
H O
HO
D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D013997:Time Factors
D017430:Prostate-Specific Antigen